ALX Oncology Holdings Inc. (ALXO)

NASDAQ: ALXO · Real-Time Price · USD

1.080

+0.030 (2.86%)

At close: Sep 16, 2025, 4:00 PM EDT

1.060

-0.020 (-1.85%)

Pre-market: Sep 17, 2025, 5:46 AM EDT

ALX Oncology Holdings Employees

ALX Oncology Holdings had 80 employees as of December 31, 2024. The number of employees increased by 8 or 11.11% compared to the previous year.

Employees

80

Change (1Y)

8

Growth (1Y)

11.11%

Revenue / Employee

n/a

Profits / Employee

-$1,457,163

Market Cap

57.84M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	80	8	11.11%
Dec 31, 2023	72	14	24.14%
Dec 31, 2022	58	15	34.88%
Dec 31, 2021	43	20	86.96%
Dec 31, 2020	23	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ALXO News

4 days ago - ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer - GlobeNewsWire
18 days ago - ALX Oncology to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
4 weeks ago - ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors - GlobeNewsWire
5 weeks ago - ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript - Seeking Alpha
5 weeks ago - ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
6 weeks ago - ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
3 months ago - ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
4 months ago - ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - GlobeNewsWire